erlotinib hydrochloride has been researched along with lde225 in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (lde225) | Trials (lde225) | Recent Studies (post-2010) (lde225) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 167 | 23 | 160 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | lde225 (IC50) |
|---|---|---|---|
| Sonic hedgehog protein | Mus musculus (house mouse) | 0.0055 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cherpelis, B; Rudnick, EW; Thareja, S | 1 |
1 review(s) available for erlotinib hydrochloride and lde225
| Article | Year |
|---|---|
Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
Topics: Administration, Oral; Anilides; Antineoplastic Agents; Biphenyl Compounds; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Hedgehog Proteins; Molecular Targeted Therapy; Phthalazines; Podophyllotoxin; Pyridines; Quinazolines; Receptor, IGF Type 1; Retinoids; Skin Neoplasms; Tumor Burden | 2016 |